Effect of antiviral therapy on long-term prognosis of patients with decompensated hepatitis B cirrhosis

Yang HanZe

doi:10.3969/j.issn.1001-5256.2016.06.016

Issue 6

Jun. 2016

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2016 > 32(6): 1104-1107

PDF( 1574 KB)

Effect of antiviral therapy on long-term prognosis of patients with decompensated hepatitis B cirrhosis

DOI: 10.3969/j.issn.1001-5256.2016.06.016

Yang HanZe

Published Date: 2016-06-20

Abstract

Abstract

Objective To investigate the effect of antiviral therapy on the long- term prognosis of patients with decompensated hepatitis B cirrhosis.Methods A total of 132 patients with decompensated hepatitis B cirrhosis who were hospitalized in The People's Hospital of Lezhi County 3 times or more from May 2009 to May 2012 were enrolled in the study.According to the therapies,the patients were divided into control group(51 patients) and observation group(81 patients).All the patients were followed up for 5 years via outpatient service and by telephone.Child- Pugh score and Model for End- Stage Liver Disease(MELD) score were obtained from all patients,and the reduction in HBV DNA,HBV DNA clearance,and liver function parameters were observed.Clinical outcomes were compared at the end of follow- up between the two groups.The t- test was used for comparison of continuous data between groups,and the chi- square test was used for comparison of categorical data between groups.Results The observation group had significantly lower incidence rate of liver cancer,rate of liver transplantation,and mortality rate than the control group(χ2= 4.32,4.33,and 4.71,all P < 0.001).After treatment,the observation group showed a significant reduction in HBV DNA level(t = 20.60,P < 0.001) and had a significantly lower HBV DNA level than the control group(t = 16.40,P < 0.05).After treatment,the observation group had a significantly higher cumulative clearance rate of HBV DNA than the control group(88.89% vs 6.67%,P < 0.05).After treatment,the observation group had a significantly higher serum albumin level and significantly lower levels of total bilirubin(TBil) and alanine aminotransferase(ALT) than the control group(t = 6.77,16.60,and 11.67,all P < 0.001),and both groups showed significant reductions in TBil and ALT after treatment(observation group:t = 25.18 and 23.33,both P < 0.001;control group:t = 6.15 and 7.20,both P < 0.001).The observation group showed a significant increase in serum albumin level after treatment(t = 10.08,P < 0.001).After treatment,the observation group had significantly lower Child- Pugh score and MELD score than the control group(t = 2.27 and 2.24,both P < 0.05),both groups showed significant reductions in Child- Pugh score and MELD score(observation group:t = 9.18 and 8.17,P < 0.001 and P = 0.03;control group:t = 2.93 and 3.12,P = 0.01 and0.04).Conclusion Long- term antiviral therapy can improve the long- term prognosis of patients with decompensated hepatitis B cirrhosis and increase the 5- year survival rate.
- liver cirrhosis,
- therapy,
- prognosis

FullText(HTML)

References(15)

References

[1]HUANG YB,QIAO Y,CHANG LS,et al.Effect of antiviral therapy on prognosis of patients with decompensated cirrhosis[J].Chin JGastroenterol Hepatol,2011,20(4):331-334.(in Chinese)黄玉波,乔雍,常路丝,等.抗病毒治疗对失代偿期乙肝肝硬化患者预后的影响[J].胃肠病学和肝病学杂志,2011,20(4):331-334.

[2]LI P,DING HG.Early diagnosis and screening of hepatocellular carcinoma in high-risk popular[J].Chin J Pract Intern Med,2015,35(3):193-193.(in Chinese)李鹏,丁惠国.肝癌危险因素及早期诊断与筛查[J].中国实用内科杂志,2015,35(3):193-195.

[3]LI YJ.Evaluation on efficacy and safety of adefovir dipivoxil combined with lamivudine treatment for hepatitis B virus-related decompensated cirrhosis patients[J].Pract Pharm Clin Remed,2012,15(12):822-824.(in Chinese)李云静.阿德福韦酯联合拉米夫定治疗乙肝肝硬化失代偿期的疗效及安全性评价[J].实用药物与临床,2012,15(12):822-824.

[4] Chinese Society of Hepatology Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B(2010 version)[J].J Clin Hepatol,2011,27(1):Ⅰ-ⅩⅥ.(in Chinese)中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南[J].临床肝胆病杂志,2011,27(1):Ⅰ-ⅩⅥ.

[5]LUO HF,YANG XA,ZHANG K,et al.Efficacy observation of mesenchymal stem cells derived from human umbilical cord for therapy of hepatitis B patients with decompensated cirrhosis[J].Chinese J Exp Clin Virol,2015,29(3):239-241.(in Chinese)骆海飞,杨小安,张卡,等.人脐带间充质干细胞治疗乙肝肝硬化失代偿期疗效观察[J].中华实验和临床病毒学杂志,2015,29(3):239-241.

[6]ZHANG JX,YAN J,WEI Y,et al.A cross-sectional survery on the cognition of common sense treatments on liver cirrhosis complications[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition,2015,9(3):401-404.(in Chinese)张俊霞,闫杰,魏阳,等.乙型肝炎肝硬化失代偿期患者对肝硬化并发症治疗常识的认知现状调查[J/CD].中华实验和临床感染病杂志:电子版,2015,9(3):401-404.

[7]ZHANG QJ,ZHANG J,LI Y,et al.Clinical study of entecavir in the treatment of hepatitis B decompensated liver cirrhosis[J].JGuiyang Coll Tradit Chin Med,2011,33(3):60-62.(in Chinese)张勤俭,张建,李燕,等.恩替卡韦治疗乙肝肝硬化失代偿期的临床研究[J].贵阳中医学院学报,2011,33(3):60-62.

[8]FENG JH.Therapeutic effects of entecavir therapy for patients with hepatitis B virus related decompensated cirrhosis[J].Med Philosophy,2011,32(8):29-30.(in Chinese)冯继红.恩替卡韦治疗失代偿期乙肝肝硬化临床疗效观察[J].医学与哲学,2011,32(8):29-30.

[9]FU WZ,YANG L.Clinical features and prognoses of decompensated liver cirrhosis of hepatitis B with different viral loads[J].Chin Gen Pract,2013,16(14):1672-1674.(in Chinese)付万智,杨丽.不同病毒载量乙型肝炎肝硬化失代偿期患者的临床特征及转归情况分析[J].中国全科医学,2013,16(14):1672-1674.

[10]NIE QH.Clinical practice of antiriral treatment for liver cirrhosis patients with chronic hepatitis B[J].Chin J Pract Intern Med,2014,34(6):568-571.(in Chinese)聂青和.核苷酸类似物药物治疗乙型肝炎肝硬化的临床实践[J].中国实用内科杂志,2014,34(6):568-571.

[11]YANG Y,CHEN JS,OU XJ,et al.Follow up study of HBV-induced decompensated cirrhosis treated with nucleot(s)ide analogues[J].J Capit Med Univ,2010,31(5):573-577.(in Chinese)杨烨,陈景寿,欧晓娟,等.核苷(酸)类似物治疗失代偿期乙肝肝硬化的随访研究[J].首都医科大学学报,2010,31(5):573-577.

[12]TANG MG.Clinical study of nucleoside(nucleotide)analogues in the treatment of decompensated hepatitis B cirrhosis[J].Mod J Integr Tradit Chin West Med,2015,(3):301-303.(in Chinese)汤茂刚.核苷(酸)类似物治疗乙型肝炎肝硬化失代偿期临床研究[J].现代中西医结合杂志,2015,(3):301-303.

[13]YANG QE,JIANG YM,SUN T,et al.The clinical curative effect of lamivudine combined with adefovir dipivoxil in senile decompensated liver cirrhosis[J].Chin J Gerontol,2015,35(6):1518-1520.(in Chinese)杨崎恩,蒋亦明,孙彤,等.拉米夫定联合阿德福韦酯治疗老年失代偿期乙肝后肝硬化的临床疗效[J].中国老年学杂志,2015,35(6):1518-1520.

[14]LIU YS.Clinical observation on adefovir dipivoxil tablets in the treatment of elderly patients with decompensated hepatitis B cirrhosis[J].Chin J Gerontol,2011,31(18):3634-3635.(in Chinese)刘岩山.阿德福韦酯片治疗老年失代偿期乙型肝炎肝硬化的临床观察[J].中国老年学杂志,2011,31(18):3634-3635.

[15]LI JM.The curative effect and safety of telbivudine in the treatment of decompensated hepatitis B cirrhosis[J].Shandong Med J,2011,51(16):73-74.(in Chinese)李景明.替比夫定治疗失代偿期乙肝肝硬化的疗效及安全性[J].山东医药,2011,51(16):73-74.

Relative Articles

[1]	Xiaoqin ZHU, Na WEI, Yong XIAO, Baoping YU. Impact of hepatocellular carcinoma on the prognosis of patients with liver cirrhosis undergoing emergency endoscopic therapy due to esophagogastric variceal bleeding[J]. Journal of Clinical Hepatology, 2025, 41(2): 277-283. doi: 10.12449/JCH250213
[2]	Yuhang CHEN, Zimeng JIANG, Zhijiao ZHANG, Mengyao ZHENG, Meilian WANG, Hua HUANG, Gongfang ZHAO. The influence of diagnostic criteria of different guidelines on short-term prognosis of artificial liver therapy for acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2023, 39(11): 2629-2634. doi: 10.3969/j.issn.1001-5256.2023.11.017
[3]	Bangting ZHANG, Ying XU, Xuefang YANG, Xue Zhang. Association of sarcopenia with prognosis after transjugular intrahepatic portosystemic shunt in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2021, 37(12): 2932-2934. doi: 10.3969/j.issn.1001-5256.2021.12.041
[4]	Lan XiaoQin, Ji YaLi, Chen JinJun, Zhou FuYuan, Wen WeiQun. Effect of artificial liver support therapy on the short-term prognosis of patients with liver failure in the plateau stage: A stratified analysis based on Model for End-Stage Liver Disease score[J]. Journal of Clinical Hepatology, 2020, 36(9): 2005-2009. doi: 10.3969/j.issn.1001-5256.2020.09.019
[5]	Zou SongLong, Xu Ying. Prognostic evaluation of transjugular intrahepatic portosystemic shunt in treatment of cirrhotic portal hypertension[J]. Journal of Clinical Hepatology, 2019, 35(1): 201-204. doi: 10.3969/j.issn.1001-5256.2019.01.044
[6]	Li TianTian, Sun Jing, Wang Quan, Ding JunQiang, Wang Jia, Xue Hui, Zhang Tao, Duan XueZhang. Clinical effect of stereotactic body radiotherapy in treatment of patients with small hepatocellular carcinoma and related prognostic factors[J]. Journal of Clinical Hepatology, 2018, 34(8): 1702-1706. doi: 10.3969/j.issn.1001-5256.2018.08.022
[7]	Tang Wen, Wang Yu, Zhao XinYan, Wang XiaoMing, Ou XiaoJuan, Jia JiDong. Impact of portal vein thrombosis on prognosis of patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2017, 33(3): 466-471. doi: 10.3969/j.issn.1001-5256.2017.03.014
[8]	Li MengGe, Zhao YaLin, Liu XiaoLi, Wang XinHui, Jiang YuYong, Yang ZhiYun. Effect of different minimally invasive therapies on the prognosis of patients with HBV-related primary liver cancer complicated by portal vein tumor thrombus[J]. Journal of Clinical Hepatology, 2017, 33(4): 684-688. doi: 10.3969/j.issn.1001-5256.2017.04.017
[9]	Li Shuang, Lu Wei, Cui ShuBo, Li Jia, Hu DongSheng, Zhou YongHe, Yao ShengJuan. Role of endoscopic ultrasonography in treatment and prognostic evaluation of esophageal and gastric varices[J]. Journal of Clinical Hepatology, 2016, 32(12): 2268-2272. doi: 10.3969/j.issn.1001-5256.2016.12.008
[10]	Zhang HuiKai, Meng XiangLin, Li HaiLei, Xu YuLing, Luo HongWei. Current status of malnutrition and its association with prognosis in hospitalized patients with decompensated liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(6): 1100-1103. doi: 10.3969/j.issn.1001-5256.2016.06.015
[11]	Ju Wei, Zhang BoJing, Han GuoHong. Long-term therapeutic effect of transjugular intrahepatic portosystemic shunt in patients with intractable cirrhotic ascites and prognostic factors[J]. Journal of Clinical Hepatology, 2016, 32(8): 1529-1533. doi: 10.3969/j.issn.1001-5256.2016.08.019
[12]	Lin Jing, Wei Bo, Wu Hao, Tong Huan, Tang ChengWei. Effect of antiviral therapy on prognosis of patients with decompensated hepatitis B cirrhosis undergoing transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2016, 32(2): 254-258. doi: 10.3969/j.issn.1001-5256.2016.02.011
[13]	Sun YaMeng, You Hong. Advances in staging and treatment of hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(6): 1036-1039. doi: 10.3969/j.issn.1001-5256.2016.06.003
[14]	Lin Feng. Research advances in clinical diagnosis,prognostic evaluation,and treatment of liver failure[J]. Journal of Clinical Hepatology, 2016, 32(9): 1678-1683. doi: 10.3969/j.issn.1001-5256.2016.09.009
[15]	Huang ChunYang, Liu YanMin. Prognostic evaluation of primary biliary cirrhosis and its value in guiding therapeutic regimens[J]. Journal of Clinical Hepatology, 2016, 32(7): 1266-1272. doi: 10.3969/j.issn.1001-5256.2016.07.009
[16]	Li Peng, Zhai Yun, Zhang ShiBin, Li Lei, Ding HuiGuo. Analysis of quality of life and prognosis in patients with HBV-related end-stage hepatocellular carcinoma after antiviral therapy[J]. Journal of Clinical Hepatology, 2015, 31(5): 721-724. doi: 10.3969/j.issn.1001-5256.2015.05.021
[17]	Zhang JingWen, Shi YongQuan, Han Ying. Progress in treatment of liver cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(3): 465-468. doi: 10.3969/j.issn.1001-5256.2015.03.037
[18]	Tian Yan, Hu NaiZhong. Value of five-stage prognostic system in predicting short-term outcome of patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(3): 387-391. doi: 10.3969/j.issn.1001-5256.2015.03.018
[19]	Jia Jia, Qi XingShun, Han GuoHong. Prognostic value of α-fetoprotein response in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2013, 29(8): 576-580. doi: 10.3969/j.issn.1001-5256.2013.08.006

Supplements(0)

Cited By

Cited by

Periodical cited type(5)

1.	郭香娟，王敏，张洪涛，卢力飞，宋欢欢，范晓英，聂尚燕，郭红，张肖. 水飞蓟素胶囊联合替诺福韦对失代偿期乙肝肝硬化患者肝肾功能、肝纤维化及氧化应激水平的影响. 疑难病杂志. 2020(10): 980-984 .
2.	邓小艳. 失代偿期乙型肝炎肝硬化的临床特点及抗病毒治疗预后评价. 名医. 2018(10): 58 .
3.	吴雄健，郑虹，朱海燕，张蕾，毛忠懿，谢军. MELD评分系统及Child-Pugh分级评估乙型肝炎肝硬化失代偿期患者的预后研究. 赣南医学院学报. 2017(04): 542-544 .
4.	程辉，袁宇慧. 不同核苷(酸)类抗病毒药物在失代偿期乙型肝炎肝硬化患者治疗中的应用. 安徽医药. 2016(12): 2327-2331 .
5.	杨俊晓，赵元琳. 肝硬化并发症的预防与治疗. 世界最新医学信息文摘. 2016(98): 177 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2401) PDF downloads(405)

Effect of antiviral therapy on long-term prognosis of patients with decompensated hepatitis B cirrhosis

DOI: 10.3969/j.issn.1001-5256.2016.06.016